ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

ClinicalTrials.gov ID: NCT02971761

Public ClinicalTrials.gov record NCT02971761. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 12:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)

Study identification

NCT ID
NCT02971761
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
City of Hope Medical Center
Other
Enrollment
18 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2017
Primary completion
Oct 27, 2020
Completion
Aug 15, 2022
Last update posted
Feb 19, 2024

2017 – 2022

United States locations

U.S. sites
7
U.S. states
1
U.S. cities
7
Facility City State ZIP Site status
City of Hope Corona Corona California 92879
City of Hope Medical Center Duarte California 91010
City of Hope Antelope Valley Lancaster California 93534
City of Hope Mission Hills Mission Hills California 91345
City of Hope Rancho Cucamonga Rancho Cucamonga California 91730
City of Hope South Pasadena South Pasadena California 91030
City of Hope West Covina West Covina California 91790

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02971761, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 19, 2024 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02971761 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →